Skip to main content

Genes for Improved Cancer Diagnosis

Paige Launches AI Tool that Screens 505 Genes for Improved Cancer Diagnosis



AI startup Paige launched a new AI product this week. The New York City-based company unveiled an AI-powered biomarker module that the company says can evaluate more than 505 genes and identify 1,228 molecular biomarkers from standard pathology slides.

The new product, called OmniScreen, analyzes digital images of cancer tissue slides that are stained using hematoxylin and eosin (H&E).

“These slides contain important visual patterns linked to genetic changes in cancer cells. By training our AI on three million of these images, it learns to recognize patterns and in turn detects genetic mutations or biomarkers that are often used to guide cancer treatment decisions,” explained Razik Yousfi, Paige’s CEO and chief technology officer.

In oncology, gene mutations are important in determining what type of cancer a patient has and what treatments will be most effective, he noted.

When people hear “breast cancer,” most think it is just one disease, he said. But the reality is that it can be one of many different types, all of which require unique approaches to treatment, Yousfi pointed out.

“Omniscreen could be valuable in detecting these subtypes across many different types of cancer. Whereas other methods, such as gene sequencing, are expensive and time consuming, Omniscreen can be done quickly and more cost effectively directly from the tissue sample using AI,” he declared.

While Omniscreen is currently only available for research, it allows researchers to better characterize disease and develop improved therapies for patients, Yousfi added.

In his view, Omniscreen is cheaper and faster than other methods for detecting gene mutations and alterations. Rather than completely replacing these other methods, Yousfi believes there is an opportunity to decrease the costs associated with gene analysis for precision medicine.

“By screening patients quickly using Omniscreen, we could identify quickly which patients are negative for certain mutations and use these to select patients for more complex, expensive testing. In research, Omniscreen gives cancer researchers a convenient, fast and cheaper approach to studying cancer and building better and more effective markers to improve cancer care,” he remarked.

This applies to cancer research conducted at hospitals, universities and pharmaceutical facilities for the development of new cancer drugs, Yousfi noted.

X-chromosome inactivation, telomere length, recurrent pregnancy loss, RPL, miscarriage, skewed XCI, cellular aging, genetic factors, pregnancy outcomes, female fertility, chromosomal abnormalities, maternal age, reproductive health, embryonic development, immune response, telomere shortening, fertility treatment, genetic screening, epigenetics, pregnancy complications,

#XChromosomeInactivation, #TelomereLength, #RecurrentPregnancyLoss, #RPL, #Miscarriage, #SkewedXCI, #CellularAging, #GeneticFactors, #PregnancyOutcomes, #FemaleFertility, #ChromosomalAbnormalities, #MaternalAge, #ReproductiveHealth, #EmbryonicDevelopment, #ImmuneResponse, #TelomereShortening, #FertilityTreatment, #GeneticScreening, #Epigenetics, #PregnancyComplications


International Conference on Genetics and Genomics of Diseases 




For Enquiries: genetics@healthcarek.com 

Get Connected Here 
--------------------------------- 
--------------------------------- 
facebook.com/profile.php?id=61555903296992 
tumblr.com/blog/dorita0211 

Comments

Post a Comment

Popular posts from this blog

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Post-Stroke Cardiovascular risks

Study finds genetic factors key to post-stroke cardiovascular risks In a recent study published in the journal Stroke , researchers identify genetic and molecular risk factors for subsequent cardiovascular outcomes after incident stroke in an effort to identify potential therapeutic targets to improve patient prognoses. Identifying the causes of stroke Stroke is a major global health issue that causes significant disability and mortality, particularly arterial ischemic stroke (AIS). AIS, which is a type of stroke caused by blocked blood flow to the brain, is responsible for up to 85% of stroke cases. AIS arises due to cerebral blood vessel blockage, with modifiable risk factors including hypertension, diabetes, dyslipidemia, atrial fibrillation, obesity, and lifestyle behaviors. Although genome-wide association studies (GWAS) often focus on incident strokes, studying subsequent events can provide new insights into stroke progression. Further research is crucial to identify genetic and...
Post a Comment
Read more

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more